Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

Have you ever searched for information about side effects of a medication? These days, most people put the name of their drug into a search engine along with the phrase “side effects.” Whatever comes ...

At the end of the day, GLP-1s can be a powerful tool for achieving your weight loss goals, but only if they're safe and ...

How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...